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BACKGROUND: Delta-like ligand 4 (Dll4) is a Notch ligand that is upregulated by hypoxia and vascular endothelial growth factor-A
(VEGF-A) and is reported to have a role in tumor angiogenesis. Evidence from xenograft studies suggests that inhibiting Dll4–Notch
signalling may overcome resistance to anti-VEGF therapy. The aim of this study was to characterise the expression of Dll4 in colon
cancer and to assess whether it is associated with markers of hypoxia and prognosis.
METHOD: In all, 177 colon cancers were represented in tissue microarrays. Immunohistochemistry was performed using validated
antibodies against Dll4, VEGF, hypoxia-inducible factor (HIF)-1a, HIF-2a, prolyl hydroxylase (PHD)1, PHD2, PHD3 and carbonic
anhydrase 9 (CA9).
RESULTS: The expression of Dll4 was observed preferentially in the endothelium of 71% (125 out of 175) of colon cancers, but not in
the endothelium adjacent to normal mucosa (none out of 107, Po0.0001). The expression of VEGF was significantly associated with
HIF-2a (Po0.0001) and Dll4 (P¼0.010). Only HIF-2a had a significant multivariate prognostic effect (hazard ratio 1.61, 95%
confidence interval 1.01–2.57). Delta-like ligand 4 was also expressed by neoplastic cells, particularly neoplastic goblet cells.
CONCLUSION: Endothelial expression of Dll4 is not a prognostic factor, but is significantly associated with VEGF. Assessing endothelial
Dll4 expression may be critical in predicting response to anti-VEGF therapies.
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Colorectal cancer is the second most common cause of cancer
deaths worldwide, with an estimated 1023152 new cases and
528978 related deaths in 2002(Parkin et al, 2005). The early growth
of colorectal tumours requires angiogenesis (Goodlad et al, 2006;
Korsisaari et al, 2007), the consequence of increased expression of
pro-angiogenic factors (e.g., vascular endothelial growth factor-A
(VEGF-A); Ferrara et al, 1991; Kim et al, 1993; Jubb et al, 2003;
Korsisaari et al, 2007). The expression of VEGF in cancer is
controlled by both oncogenic signalling (such as Wnt-signalling in
colorectal cancer; Zhang et al, 2001) and hypoxia (Mizukami et al,
2004). Although there is redundancy among pro-angiogenic factors
in advanced cancer (Relf et al, 1997; Hanrahan et al, 2003), many
early cancers (Hanrahan et al, 2003; Jubb et al, 2003) and in vivo
cancer models (Bergers et al, 1999; Hanrahan et al, 2003; Joyce
et al, 2003; Goodlad et al, 2006; Korsisaari et al, 2007) are VEGF
dependent. This observation has been exploited by the addition of
an anti-VEGF monoclonal antibody (bevacizumab) to first-line
chemotherapy in metastatic colorectal cancer, which prolonged the
median overall survival (from 15.6 to 20.3 months, P¼0.001;
Hurwitz et al, 2004). Nevertheless, all patients in this trial
eventually progressed after 2 years (Jubb et al, 2006b), and there
are no valid predictors of the survival benefit afforded by
bevacizumab in colorectal cancer (Ince et al, 2005; Jubb et al,
2006a; Grothey et al, 2008a,b).
Additional therapeutic agents that disrupt functional tumour
angiogenesis have been developed to target tumours that are
inherently resistant to anti-VEGF therapy or become resistant
during the course of therapy (Noguera-Troise et al, 2006; Ridgway
et al, 2006; Pan et al, 2007; Caunt et al, 2008). Delta-like Ligand 4
(Dll4) is a ligand for Notch 1, 3 and 4 proteins, which is expressed
by endothelial cells (Thurston et al, 2007; Indraccolo et al, 2009)
and may be induced by VEGF and hypoxia, through hypoxia-
inducible factor (HIF)-1a (Patel et al, 2005). In the retina, the
interaction between Dll4 and Notch regulates endothelial sprouting
and branching to form functional vascular beds (Hellstrom et al,
2007). Disruption of Dll4 signalling by overexpression or inhibi-
tion of Dll4 may impair tumour angiogenesis (Noguera-Troise
et al, 2006; Ridgway et al, 2006), and blockade of Dll4–Notch
signalling results in an increased density of non-functional
vasculature and is associated with a reduction in the growth of
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shuman xenografts (Noguera-Troise et al, 2006; Ridgway et al, 2006).
Indeed, certain xenografts that are resistant to anti-VEGF therapy
are reported to be sensitive to anti-Dll4 (Noguera-Troise et al,
2006; Ridgway et al, 2006; Li et al, 2007), and combination
treatment with anti-VEGF and anti-Dll4 has additive effects on
tumour growth (Ridgway et al, 2006). In addition, human
umbilical vein endothelial cells transfected with Dll4 downregulate
the VEGF receptor 2 and co-receptor neuropilin-1, and show
reduced proliferative and migratory responses to VEGF (Williams
et al, 2006). Together, these data suggest that Dll4 may have a role
in mediating resistance to anti-VEGF therapies.
The characterisation of Dll4 protein expression in human cancer
is important for the rational design of clinical trials to test the
safety and activity of anti-Dll4 therapy. Moreover, defining the
context of Dll4 expression, in terms of known markers of hypoxia
and angiogenesis, may identify subgroups of tumours with distinct
clinical behaviour and response to treatment. The aims of this
study were to characterise the in situ expression of Dll4 in colon
cancer, to assess the association between Dll4 and established
markers of hypoxia and angiogenesis and to determine the
prognostic significance of these markers.
PATIENTS AND METHODS
Cell lines
Recombinant human Dll4 was cloned into a pcDNA3.1 vector
(Invitrogen, Carlsbad, CA, USA). Vectors were transfected into
human U87 cells with the Fugene 6 transfection reagent (Roche
Applied Science, Indianapolis, IN, USA). Human umbilical vein
endothelial cells were cultured in vitro in media with and without
VEGF as previously described (Harrington et al, 2007). Cell pellets
were then formalin fixed and paraffin embedded. Further details
are available from the authors on request.
Patients and tissue samples
Formalin-fixed and paraffin-embedded tissue blocks and corre-
sponding pathology reports were retrospectively obtained for 177
sequential patients with colon adenocarcinomas (surgery was
performed from 1997 to 2000 at the John Radcliffe Hospital,
Oxford, UK). Sample size was determined by the availability of
tissue with full clinicopathological data, survival follow-up and
ethical approval for research. No patients received preoperative
chemotherapy. Rectal cancers were excluded from this series to
avoid the confounding effects that preoperative radiotherapy may
have on the expression of hypoxic markers. The mean age at
diagnosis was 71 years (range 17–92 years), 97 patients (55%) were
male and 73 cancers (41%) were at or distal to the splenic flexure.
In all, 13 cancers were in Dukes’ stage A (7%), 88 in stage B (50%),
55 in stage C (31%) and 21 in stage D (12%) at the time of surgery.
The mean follow-up time was 5.6 years (range 1 month to 11.9
years). No patients received postoperative radiotherapy. No Dukes’
stage A patients, 38% (24 out of 64) of Dukes’ stage B patients, 58%
(32 out of 55) of Dukes’ stage C patients and 52% (11 out of 21) of
Dukes’ stage D patients received 5-fluorouracil-based chemotherapy
according to the local protocols (adjuvant regimen: six 5-day
courses of 370mgm
 2 5-fluorouracil and 25mg L-folinic acid as an
intravenous bolus every 4 weeks). Follow-up data were correct as of
January 2009, with a median follow-up time of 5 years and
7 months. Tissue microarrays were assembled as described
previously (Bubendorf et al, 2001) with three replicate cores for
each tumour and one core for each normal mucosal sample. An
additional 12 whole sections of colorectal adenomas with adjacent
adenocarcinoma were also collected (John Radcliffe Hospital) to
further analyse the expression of Dll4 in the adenoma to
adenocarcinoma sequence. Approval was obtained for the use of
all human tissue from the local research ethics committee (C02.216).
In situ hybridisation
Isotopic in situ hybridisation for Dll4 was performed using
previously described methods (Poulsom et al, 1998). The probe
used was a 741-bp cloned fragment of human Dll4 (position 1775
to 2516bp, relative to the adenosine of the start codon ATG; Patel
et al, 2006). In situ hybridisation for b-actin was used as a positive
control for mRNA integrity.
Immunohistochemistry
Immunohistochemistry for VEGF (clone VG1; Turley et al, 1998;
Boddy et al, 2005), HIF-1a (clone 54, BD Transduction Laboratories,
San Jose, CA, USA) (Wiesener et al,2 0 0 1 ) ,H I F - 2 a (clone EP190/E10;
Talks et al,2 0 0 0 ;B o d d yet al, 2005), prolyl hydroxylase 1 (PHD1)
(clone 112/E8), PHD2 (clone 366G/76/3), PHD3 (clone EG188e/E6)
(Appelhoff et al, 2004; Boddy et al, 2005; Soilleux et al, 2005) and
carbonic anhydrase 9 (CA9) (clone M75, a gift from Professors S
Pastorekova and J Pastorek, Institute of Virology, Slovak Academy
of Sciences, Bratislava, Slovak Republic) (Pastorekova et al, 1992;
Loncaster et al, 2001) was performed using antibodies as previously
described. Validation of all antibodies has been previously under-
taken and published by our group using cells transfected with the
relevant targets (see references listed above). Unless otherwise
stated, all antibodies were made in the Nuffield Department of
Clinical Laboratory Sciences at the University of Oxford, UK.
Immunohistochemistry for Dll4 was performed using an anti-
Dll4 monoclonal antibody (the variable regions of this antibody are
fully human and the Fc-domain is mouse; clone 242) that binds to
the extracellular domain of human Dll4 (the epitope is in EGF-like
domains 3–5 and generated in VelocImmune mice (Regeneron
Pharmaceuticals, Inc., Tarrytown, NY, USA)). In brief, antigen
retrieval was performed in target retrieval solution (Dako, Carpin-
teria, CA, USA) using a Decloaking Chamber (Biocare Medical,
Concord, CA, USA). Sections were incubated for 16h at 4
oCw i t ht h e
primary antibody at 1mgml
 1. Bound antibody was labeled with
Novolink polymer (Leica Microsystems, Bannockburn, IL, USA),
visualised using 2,3-diaminobenzidine chromogen and counter-
stained with hematoxylin. Control sections of bladder cancer and
normal kidney were included to assess the specificity of the antibody.
Staining for HIF-1a and HIF-2a was scored positive if expression
was observed in any epithelial cell nuclei. Cores were scored positive
for CA9 if membranous expression was observed in 410% of
epithelial cells. Staining for VEGF, PHD1, PHD2 or PHD3 was scored
positive if cytoplasmic expression was observed in 410% of
epithelial cells. Cores were scored positive for Dll4 if expression
was observed in any endothelial cells. In addition, Dll4 was scored in
the neoplastic cells within TMA cores in which it was observed at
high levels, that is, levels that approximated the intensity of Dll4
expression by endothelial cells. The highest intensity score among
replicate cores was used as the score for each patient. Assays and
scoring were performed blind to clinical and pathological data
(withheld for analysis until all data were complete).
Statistics
The w
2 test was used to evaluate associations between categorical
variables. The Student’s t-test was used to evaluate associations
between continuous and categorical variables. The Benjamini and
Hochberg false discovery rate controlling procedure was used to
eliminate spurious statistical associations as a result of multiple
testing (Benjamini and Hochberg, 1995). All survival analyses refer
to overall survival times, in which death from any cause represents
an event. Marker values were assessed as ordinal categorical data
in survival analyses. Median overall survival times within each
subgroup were estimated from Kaplan–Meier curves. Patients
were censored in survival analyses according to the date last seen
by a doctor. The log-rank (Mantel–Cox) test was used to assess the
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ssignificance of univariate survival analyses. For multivariate
survival models, a Cox regression analysis was used to identify
independent prognostic factors. All statistical analyses were
carried out using SPSS Statistics (version 16.0, SPSS, Chicago, IL,
USA). The two-sided P-values of o0.05 were considered
statistically significant. Cases with missing data were omitted
from statistical analyses.
Reporting recommendations for tumour marker
prognostic studies (REMARK) criteria
The REMARK criteria of the National Cancer Institute were used in
the design, analysis and interpretation of this research (McShane
et al, 2005).
RESULTS
Frequency and pattern of expression of hypoxia-regulated
proteins
Analyses of tumours from the 177 patients yielded informative
data on 155 to 177 patients. Results were not available for the
remaining cases in certain assays because of the limited amounts
of tissue represented in the tissue microarrays.
In all, 39% (60 out of 155) and 53% (85 out of 159) of colon
cancers were positive for nuclear HIF-1a and HIF-2a expression,
respectively; 21% of cases (31 out of 147) expressed both HIF-1a
and HIF-2a and 51% of cases (75 out of 147) expressed either
HIF-1a or HIF-2a. In addition, HIF-1a expression was only
observed in cell nuclei when present (Figure 1A), as previously
described (Jubb et al, 2004). The expression of HIF-2a by
neoplastic cells was predominantly cytoplasmic, with nuclear
expression in a proportion of cases (Figure 1B; Talks et al, 2000).
The expression of HIF-2a was also observed in a proportion of
infiltrating inflammatory cells as previously reported (Talks et al,
2000), although these data were not specifically recorded. The
expression of VEGF was observed in the cytoplasm of neoplastic
cells (88%, 149 out of 169), stromal fibroblasts, inflammatory cells,
endothelial cells and the extracellular matrix (Figure 1C), as
previously reported (Jubb et al, 2006a).
The PHD family of HIF-regulatory proteins is expressed in the
cytoplasm of the majority of colon cancers (Figures 1D–F), similar
to prostate cancer (Boddy et al, 2005). Prolyl hydroxylase 1 was
present in 72% (116/162), PHD2 in 82% (135/164) and PHD3 in
200 m 200 m
200 m
200 m 200 m
200 m
Figure 1 Representative examples of immunohistochemistry in colon cancer showing nuclear HIF-1a (A) and HIF-2a (B) expression, and cytoplasmic
VEGF (C), PHD1 (D), PHD2 (E) and PHD3 (F) expression.
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s70% (120/172) of colon cancers. Similarly, the majority of colon
cancers show strong membranous expression of the HIF-1 target
gene CA9 (67%, 110/165; Figure 2A), consistent with other series
(Rasheed et al, 2009).
Validation of the anti-Dll4 antibody
The human monoclonal antibody (clone 242) that specifically
recognises the extracellular domain of human Dll4 did not stain
U87 cells transiently transfected with empty vector (Supplemen-
tary Figure 1A), but showed membranous and cytoplasmic
staining in U87 cells transiently transfected with the recombinant
human Dll4 full-length gene (Supplementary Figure 1B). Human
umbilical vein endothelial cells showed immunoreactivity for Dll4
that was greater in intensity when cells were treated with VEGF
(Supplementary Figures 1C and D). Normal kidney did not express
Dll4, but endothelial cells in renal cell carcinoma showed
endothelial expression of Dll4, consistent with previous in situ
hybridisation results (Supplementary Figures 1E and F) (Patel
et al, 2005). Serial sections of bladder cancer showed endothelial
colocalisation of Dll4 mRNA using in situ hybridisation (Patel
et al, 2006), and protein using immunohistochemistry (Supple-
mentary Figures 1D–F).
Frequency and pattern of expression of Dll4
In 71% (125 out of 175) of colon cancer tissues analysed, Dll4
expression was observed in the cytoplasm of the endothelial cells
lining vessels adjacent to cancer (Figure 2B). Membranous
localisation of Dll4 was difficult to differentiate from cytoplasmic
localisation because of the slender nature of endothelial cytoplas-
mic processes. The expression of Dll4 was only rarely observed in
the endothelial lining of large vessels around or into which cancer
cells had invaded. In the whole sections of colorectal adenomas
with adjacent adenocarcinoma, Dll4 was observed at identical
frequencies in the endothelium found in both the adenomas and
200 m 50 m
200 m 50 m
50 m 200 m
Figure 2 Representative examples of immunohistochemistry in colon cancer showing membranous CA9 adjacent necrosis (A) and endothelial Dll4 (B)
expression. Immunohistochemistry for Dll4 shows membranous and cytoplasmic endothelial expression in a colon adenoma (C) and epithelial expression
associated with goblet cell differentiation in a neoplastic crypt ((D) black arrows indicate Dll4-positive goblet cells, and red arrows indicate Dll4-negative
non-goblet cells). Dll4 is also weakly expressed by neoplastic cells without goblet cell differentiation in a colon adenocarcinoma (E). Endothelial cells lining
vessels (arrows) adjacent to normal colonic crypts did not express Dll4 by immunohistochemistry (F).
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sadenocarcinomas (12 out of 12, Figure 2C, Supplementary Figures
2A–C). The endothelium associated with colonic adenomas and
adenocarcinomas (i.e., within two low-power fields of the tumour
cells) was positive for Dll4 in 60–100% of vessels (identified by
CD34 immunoreactivity in serial sections, data not shown). Similar
levels of endothelial Dll4 expression were observed in the centre of
the tumour and at the invading edge. In all, 16% (28 out of 177) of
colon cancers represented in the tissue microarrays expressed
levels of Dll4 in the cytoplasm and membrane of neoplastic cells
that approximated the intensity of expression observed in
endothelium. In the whole sections, 410% of the malignant
epithelial cells of the colorectal adenomas and adjacent adeno-
carcinomas expressed Dll4 in 8 of 12 cases (median 30%, range
10–60%). In regions of both colorectal adenomas and adenocarci-
nomas, high levels of Dll4 expression were observed in neoplastic
epithelial cells with goblet cell differentiation (Figure 2D, Supple-
mentary Figure 2D). (Goblet cells were defined morphologically.)
Elsewhere, Dll4 was expressed at a lower level by neoplastic cells
without goblet cell morphology (Figure 2E). Endothelial cells
adjacent to normal colon mucosa distant from cancer did not
express Dll4 protein (0 out of 107). Epithelial cells lining normal
colonic crypts, irrespective of their morphology, did not express
Dll4 (Figure 2F), although occasional cells in the superficial surface
mucosa of normal colon stained weakly for Dll4 (data not shown).
Specifically, normal colonic goblet cells did not express Dll4. The
pattern of Dll4 expression by in situ hybridisation matched the
immunohistochemistry results for the 12 colorectal adenomas with
adjacent adenocarcinoma (Supplementary Figure 3).
Associations between molecular and pathological variables
Hypoxia-inducible factor-1a and CA9 were not significantly
associated with any other immunohistochemical markers in colon
cancer (Table 1). In contrast, HIF-2a was significantly associated
with VEGF, Dll4, PHD1, PHD2 and PHD3. Vascular endothelial
growth factor was significantly associated with endothelial Dll4,
PHD1, PHD2 and PHD3. Endothelial Dll4 was also significantly
associated with PHD1 and PHD3. Prolyl hydroxylase (PHD)1,
PHD2 and PHD3 were significantly associated with each other. In
addition, endothelial expression of Dll4 was negatively associated
with nuclear HIF-2a expression by tumour cells, but this
association was not significant after correction for multiple testing.
Delta-like ligand 4 expression by malignant epithelial cells was not
associated with any clinicopathological or molecular variables
(data not shown).
None of the immunohistochemical markers analysed in this
study were associated with tumour stage, lymphatic invasion,
vascular invasion, grade, sex or site after the false discovery rate
controlling procedure was used to exclude spurious results
(Table 2). Similarly, no immunohistochemical markers were
associated with age using the Student’s t-test (data not shown).
Survival
In univariate analyses, only nuclear HIF-2a (P¼0.027), pT stage
(P¼0.0003), pN stage (Po0.0001), M stage (Po0.0001), lymphatic
invasion (P¼0.007), vascular invasion (P¼0.002), grade
(P¼0.028) and adjuvant chemotherapy (P¼0.003) significantly
correlated with overall survival (Table 3, Figure 3). (Note that the
patients receiving adjuvant chemotherapy seem to have performed
worse in overall survival analyses as they disproportionately
represent advanced-stage cancers). The relationship between age
and overall survival was assessed using Cox regression; it was not
statistically significant, P¼0.10. Patients with cancers that were
positive for nuclear HIF-2a expression had a significantly shorter
median survival (57 months, 95% confidence interval 36–79
months) than patients with cancers that were negative for nuclear
HIF-2a expression (101 months, 95% confidence interval 81–121
months). In addition, HIF-2a showed statistical significance
(P¼0.044) in multivariate survival analyses (Table 4). The Cox
regression multivariate survival model also included pT stage
(Po0.05), pN stage (P¼0.009), M stage (Po0.0001), lymphatic
invasion (P¼0.32), vascular invasion (P¼0.48), grade (P¼0.56)
and adjuvant chemotherapy (P¼0.56) (Table 4). The significance
of statistical associations and survival analyses does not differ if
the intensity of staining of the immunohistochemical markers was
scored on a semiquantitative scale, as opposed to positive or
negative (data not shown).
Endothelial Dll4 expression was not a statistically significant
prognostic factor (Table 3). Although these are exploratory
analyses, power calculations for Dll4 showed a statistical power
Table 1 Statistical significance of associations between molecular
variables
Variable HIF-2a CA9 VEGF
Dll4
Endo. PHD1 PHD2 PHD3
HIF-1aw
2 o0.01 3.43 0.96 2.08 0.23 o0.01 o0.01
P 1.00 0.09 0.33 0.11 0.63 0.97 1.00
HIF-2aw
2 — o0.01 18.78 4.5 4.24 10.41 11.75
P 0.96 o0.0001 0.03*
,a 0.04* 0.001 o0.001
CA9 w
2 — o0.01 o0.01 1.45 4.53 1.11
P 1.00 1.00 0.23 0.03* 0.29
VEGF w
2 — — — 5.98 34.15 25.33 29.92
P 0.01 o0.0001 o0.0001 o0.0001
Dll4
Endo.
w
2 — — — — 5.43 0.26 7.14
P 0.01 0.61 0.008
PHD1 w
2 — — — — — 16.04 32.90
P o0.0001 o0.0001
PHD2 w
2 — — — — — — 13.85
P 0.0002
aNegative association. All associations are positive unless otherwise stated. *These
P-values are not significant after correction for multiple testing by the Benjamini and
Hochberg false discovery rate controlling procedure with a cutoff¼0.05. Abbrevia-
tions: Endo.¼endothelial; PHD1¼prolyl hydroxylase; VEGF¼vascular endothelial
growth factor; CA9¼carbonic anhydrase 9; HIF¼hypoxia-inducible factor;
Dll4¼delta-like ligand 4.
Table 2 Statistical significance of associations between molecular and
categorical clinical variables
Variable pT pN M LI VI Grade Sex Site AC
HIF-1aw
2 1.37 2.97 0.25 o0.01 1.37 6.26 0.18 5.55 1.10
P 0.71 0.40 0.62 0.94 0.24 0.04* 0.67 0.02* 0.29
HIF-2aw
2 1.08 0.37 2.87 0.24 0.49 1.79 0.03 3.64 0.45
P 0.78 0.95 0.09 0.62 0.49 0.41 0.88 0.06 0.50
CA9 w
2 2.39 4.22 0.12 0.90 0.76 2.25 0.89 4.09 0.00
P 0.50 0.24 0.73 0.34 0.38 0.33 0.27 0.04* 1.00
VEGF w
2 2.00 7.77 0.89 0.10 0.49 1.90 0.82 4.07 0.00
P 0.57 0.05 0.35 0.75 0.49 0.39 0.37 0.04* 1.00
Dll4
Endo.
w
2 0.40 1.77 o0.01 0.13 0.07 0.44 0.92 0.06 0.05
P 0.94 0.62 1.00 0.72 0.79 0.80 0.34 0.81 0.83
PHD1 w
2 9.18 3.28 0.13 0.30 0.26 9.61 0.25 o0.01 0.00
P 0.03* 0.35 0.72 0.58 0.61 0.01* 0.62 0.93 1.00
PHD2 w
2 1.83 0.99 2.28 1.09 0.11 1.05 0.12 3.80 0.00
P 0.61 0.80 0.13 0.30 0.74 0.59 0.91 0.05 1.00
PHD3 w
2 2.30 3.31 o0.01 0.60 1.43 5.99 1.43 0.80 0.09
P 0.51 0.35 0.98 0.44 0.23 0.05 0.23 0.78 0.77
Abbreviations: AC¼adjuvant chemotherapy; Endo.¼endothelial; LI¼lymphatic
invasion; VI¼vascular invasion; PHD¼prolyl hydroxylase; VEGF¼vascular
endothelial growth factor; CA9¼carbonic anhydrase 9; HIF¼hypoxia-inducible
factor; Dll4¼delta-like ligand 4. *These P-values are not significant after correction
for multiple testing by the Benjamini and Hochberg false discovery rate controlling
procedure 40 with a cutoff¼0.05.
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sof 0.882 and a hazard ratio of 0.5 for control subjects versus
experimental subjects (based on a type 1 error probability of 0.05,
an experimental group size of n¼50, a control group size of
n¼125, an accrual time of 3 years, with 5-year follow-up and a
median survival time of 6.94 years; Dupont and Plummer, 1990).
DISCUSSION
Spatial regulation of an appropriate level of Dll4 expression is
important in the development of a functional vasculature during
Table 3 Univariate analysis of overall survival
Variable N Events
Median
survival
(months)
95% Confidence
interval (months) P-value
a
Overall 177 102 83.3 58.9–107.7
HIF-1a
Negative 95 56 79.6 45.5–113.7
Positive 60 38 77.6 40.8–114.4 0.91
HIF-2a
Negative 74 37 101.5 81.5–120.7
Positive 85 55 57.4 36.1–78.7 0.027
CA9
Negative 55 32 79.6 30.2–128.9
Positive 110 66 79.1 48.1–110.1 0.87
VEGF
Negative 20 10 83.3 72.6–94.0
Positive 149 88 79.6 49.2–110.0 0.46
Dll4 Endo.
Negative 50 29 64.0 9.0–118.0
Positive 125 72 89.0 64.2–113.6 0.94
PHD1
Negative 46 26 79.1 46.0–112.2
Positive 116 69 88.9 56.2–121.6 0.71
PHD2
Negative 29 13 111.5 NR
Positive 135 83 66.7 37.7–95.7 0.08
PHD3
Negative 52 29 97.8 68.2–127.4
Positive 120 70 68.9 39.9–97.8 0.67
pT stage
15 2 N R
21 3 4 N R
3 77 37 110.9 97.9–124.0
4 82 59 45.0 32.4–57.6 0.0003
pN stage
0 103 45 139.9 98.1–181.7
1 43 31 49.2 25.6–72.7
2 28 24 18.1 1.8–34.3
3 3 2 21.1 0–43.8 o0.0001
M stage
0 156 82 100.0 82.1–118.0
1 21 20 9.2 5.1–13.3 o0.0001
LI
Absent 150 84 91.9 71.2–112.6
Present 22 16 18.0 3.6–32.5 0.007
VI
Absent 131 70 97.6 73.6–121.7
Present 41 30 23.1 0–52.4 0.002
Grade
Good 46 22 111.0 94.9–127.1
Moderate 101 64 64.0 34.1–93.9
Poor 11 8 28.9 0–83.5 0.028
Sex
Female 80 45 88.9 61.6–116.2
Male 97 57 79.6 40.3–118.8 0.68
Site
Distal 73 45 77.6 41.7–113.5
Proximal 104 57 88.9 57.7–120.0 0.50
Table 3 (Continued)
Variable N Events
Median
survival
(months)
95% Confidence
interval (months) P-value
a
AC
No 110 56 101.1 82.5–119.7
Yes 67 46 54.4 41.0–67.8 0.003
Abbreviations: AC¼adjuvant chemotherapy; Endo.¼endothelial; LI¼lymphatic
invasion; NR¼not reached; VI¼vascular invasion; PHD¼prolyl hydroxylase;
VEGF¼vascular endothelial growth factor; CA9¼carbonic anhydrase 9;
HIF¼hypoxia-inducible factor; Dll4¼delta-like ligand 4.
aLog-rank test (Mantel–Cox).
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Figure 3 Kaplan–Meier survival curves for colon cancer patients
subgrouped according to HIF-2a expression. The patients with cancers
who are positive for HIF-2a have a significantly shorter median survival
(57 months, 95% confidence interval 36–79 months) than patients with
cancers who are negative for HIF-2a (101 months, 95% confidence interval
81–121 months), P¼0.027.
Table 4 Multivariate analysis of overall survival
Variable
Hazard
ratio
95% Confidence
interval
Association with
shorter survival P-value
a
HIF-2a 1.61 1.01–2.57 Positive 0.04
pT stage 1.46 1.00–2.13 High pT o0.05
pN stage 1.60 1.13–2.26 High pN 0.009
M stage 5.19 2.65–10.14 Present o0.0001
LI 1.42 0.72–2.81 0.32
VI 1.23 0.69–2.20 0.48
Grade 1.14 0.73–1.80 0.56
AC 1.17 0.68–2.02 0.56
Abbreviations: AC¼adjuvant chemotherapy; LI¼lymphatic invasion; VI¼vascular
invasion; HIF¼hypoxia-inducible factor.
aCox regression.
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sphysiological and pathological angiogenesis (Duarte et al, 2004;
Noguera-Troise et al, 2006; Ridgway et al, 2006). Moreover,
Dll4 expression may influence the sensitivity of endothelial cells
to anti-VEGF therapy, with potential implications for the use
of bevacizumab and novel anti-Dll4 antibodies in colorectal
cancer (Noguera-Troise et al, 2006; Ridgway et al, 2006; Williams
et al, 2006; Li et al, 2007). This is the first study to perform a
detailed evaluation of Dll4 expression in colon cancer, and to relate
Dll4 expression to other known histological and prognostic
markers.
In this series of colon cancers, Dll4 expression was observed in
the cytoplasm of the endothelium lining small vessels of neoplastic,
but not normal tissue. This is consistent with data from human
xenografts (Noguera-Troise et al, 2006) and in situ hybridisation
data for Dll4 in human bladder cancer (Patel et al, 2006) and
human renal cell carcinoma (Mailhos et al, 2001; Patel et al, 2005).
The lack of expression of Dll4 in the endothelial cells and
epithelium of normal colonic crypts is consistent with the lack of
VEGF expression by normal colorectal mucosa (Jubb et al, 2003)
and the lack of intestinal toxicity and goblet cell hyperplasia
observed in anti-Dll4-treated mice (Ridgway et al, 2006). These
data suggest that strategies targeting Dll4–Notch signalling may
selectively affect the immature developing endothelium associated
with colon cancer, but not endothelium associated with normal
colonic mucosa or normal colonic crypt epithelium.
The observation of Dll4 expression by neoplastic crypts and the
association with goblet cell morphology in colon adenomas and
adenocarcinomas is novel. However, a report by van Es et al (2005)
claims that inhibiting Notch signalling in the mouse intestine
favours goblet cell differentiation in the proliferating cells of
intestinal adenomas. Together with findings presented in this
study, this suggests that both forward and reverse Notch signalling
interact to define goblet cell differentiation in proliferating
intestinal epithelium. The available data do not shed further light
on the precise roles of Dll4 and its Notch receptors in the
differentiation of goblet cells. Nevertheless, it is conceivable that
manipulating Dll4–Notch signalling may have therapeutic rele-
vance to colon cancer progression.
Activity of the hypoxia-inducible transcription factor isoforms,
HIF-1 and HIF-2, is controlled by turnover of their a-subunits,
HIF-1a and HIF-2a, respectively (Appelhoff et al, 2004). The data
show that both HIF-1a and HIF-2a are expressed at similar
frequencies in colon cancer. However, it was HIF-2a that
significantly associated with VEGF expression, suggesting that
the hypoxic induction of VEGF is predominantly controlled by
HIF-2a in colon cancer. This is consistent with data by Mizukami
et al (2004) who suggest that VEGF is induced in hypoxic
regions of colorectal cancer by an HIF-1a-independent mechanism.
Indeed, data from Knowles et al (2003) suggest that the availability
of factors, such as oxygen, ascorbate and iron, may regulate which
HIF isoform is active, even when both HIF-1 and HIF-2 are
expressed. Therefore, it is possible that the microenvironment of
colorectal cancer favours the activity of HIF-2 over
HIF-1. Carbonic anhydrase 9 is predominantly regulated by HIF-
1 (not HIF-2) activity (Sowter et al, 2003), but does not
significantly associate with HIF-1a expression in colon cancer.
This may be due to the confounding effects of the reported HIF-1-
independent induction of CA9 by hypoxia (Kaluz et al, 2002). The
positive association between endothelial Dll4 and epithelial VEGF
in colon cancer, observed in this study, is also consistent with data
from model systems in which Dll4 expression by endothelial cells
is reported to be regulated by VEGF (Patel et al, 2005). Together,
these data suggest that, in colon cancer, VEGF expression may be
regulated by HIF-2 activity and the expression of VEGF may
induce Dll4 expression in adjacent endothelial cells. This is
consistent with data reported by Skuli et al (2009) who show that
the deletion of HIF-2a in immortalised endothelial cells results in
the downregulation of Dll4 expression.
The activity of HIF-1 and HIF-2 is reported to be regulated by
hydroxylation of their a-subunits by the PHD family members
(Appelhoff et al, 2004). The hydroxylation is believed to target the
HIF-1 and HIF-2 a-subunits for destruction by the Von Hippel–
Lindau tumour suppressor protein (Appelhoff et al, 2004). In this
study the expression of the PHD proteins was strongly associated
with each other, consistent with data in prostate cancer (Boddy
et al, 2005), and suggesting that they are regulated by a common
mechanism. Expression of the PHD proteins did not significantly
associate with HIF-1a, consistent with studies in prostate cancer
(Boddy et al, 2005), but were also unexpectedly positively
associated with HIF-2a. The reasons for this are not clear, but
suggest that the role of the PHD proteins under model
physiological conditions may be different to their role in cancer.
However, PHD2 and PHD3 are targets of HIFs and are induced by
hypoxia (Appelhoff et al, 2004), which may explain the paradoxical
association, which limits the HIF effects in a well-recognised
feedback loop (D’Angelo et al, 2003). Alternatively, other factors
may regulate HIF-2a expression in colon cancer, such as iron-
deficiency anemia (Sanchez et al, 2007), confounding the data.
Further work is needed to analyse the role of the PHD proteins in
regulating HIF-1 and HIF-2 activity in human neoplasia.
In survival analyses, the absence of an observed prognostic
association for HIF-1a in colon cancer is consistent with previous
reports (Yoshimura et al, 2004). Moreover, the lack of a prognostic
association for endothelial Dll4, a VEGF target (Patel et al, 2005), is
in agreement with the lack of a prognostic association for VEGF in
colon cancer in this study and elsewhere (Nanni et al, 2002; Zheng
et al, 2003; Jubb et al, 2006a). In this study the expression of CA9
was not prognostic in terms of overall survival, in contrast to a
report that expression of CA9 is a poor prognostic factor in
colorectal cancer (Cleven et al, 2007). However, the series
described by Cleven et al (2007) includes rectal cancers that have
received neoadjuvant radiotherapy, which may confound their
results as hypoxic cells are relatively resistant to radiation-induced
cell death (Wouters and Brown, 1997). Unlike other published
studies on hypoxia in colorectal cancer, no patients in this series of
colon cancers received neoadjuvant therapy. Therefore, treatment
effects do not confound the data presented in this study.
The association between HIF-2a and prognosis in colon cancer
is consistent with previously published reports in two series of
colorectal cancers (Yoshimura et al, 2004; Cleven et al, 2007),
although our paper is the first to report the effect of HIF-2a in a
large series of large intestinal cancers that have not received
radiotherapy. Mathematical modelling suggests that hypoxic
microenvironments provide evolutionary pressure, clonally select-
ing more aggressive neoplastic cells that are able to survive
hypoxic stress (Anderson et al, 2006). Moreover, molecular
markers of hypoxia have been associated with radiation treatment
failure in rectal cancer (Korkeila et al, 2009). Together, these data
suggest that cancers expressing HIF-2a are more aggressive and
may warrant more intensive treatment.
This study has two principal limitations. First, it is exploratory,
and although the results largely agree with the literature, they have
not been internally validated. Limitations of sample size mean that
the study is not adequately powered to detect small but statistically
significant differences in survival between subsets. However, such
differences are arguably too small to be clinically significant.
Second, tissue microarrays are not always suitable for assessing
markers of hypoxia and angiogenesis. Nevertheless, provided the
cohort is large, there is sufficient core redundancy and the
prevalence of positive markers is sufficiently high (as is presented
in this study), any effects on the data should be minimised.
In summary, Dll4 is expressed in cancer-associated endothelial
cells, but not the endothelium adjacent normal colonic mucosa.
This study suggests that tumour endothelial expression of Dll4 may
not be a significant prognostic factor, but is significantly associated
with VEGF expression. In addition, Dll4 is expressed in some
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signalling can have a more direct role in colon cancer oncogenesis.
Assessing which patients express Dll4 in their tumour endothelium
may be critical in predicting response to new therapies that target
Notch or VEGF signalling. Furthermore, the antibody may be useful
for imaging the vasculature of tumours before therapy.
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